MINIREVIEWS

6031 Diabetes among Muslims during Ramadan: A narrative review

Ochani RK, Shaikh A, Batra S, Pikale G, Surani S

ORIGINAL ARTICLE

Retrospective Cohort Study

6040 Clinical evaluation of ventilation mode on acute exacerbation of chronic obstructive pulmonary disease with respiratory failure

Wang JJ, Zhou Z, Zhang LY

Retrospective Study

6051 Predictive value of preoperative albumin-bilirubin score and other risk factors for short-term outcomes after open pancreateoduodenectomy

Zavrtanik H, Cosola D, Badovinac D, Hadžialjević B, Horvat G, Plevel D, Bogoni S, Tarchi P, de Manzini N, Tomažič A

6066 Lyophilized recombinant human brain natriuretic peptide for chronic heart failure: Effects on cardiac function and inflammation

Li F, Li H, Luo R, Pei JB, Yu XY

6073 Continuous renal replacement therapy with oXiris® in patients with hematologically malignant septic shock: A retrospective study


6083 Serum basic fibroblast growth factor and interleukin-1β predict the effect of first-line chemotherapy in patients with advanced gastric cancer

Zheng L, Gan LH, Yao L, Li B, Huang YQ, Zhang FB, Kuang MQ, Fang N

6091 Multinucleated giant cells of bladder mucosa are modified telocytes: Diagnostic and immunohistochemistry algorithm and relation to PD-L1 expression score

Gulinac M, Velikova T, Dikov D

Clinical Trials Study

6105 Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients

Hegazy SK, Tharwat S, Hassan AH

META-ANALYSIS

6122 Risk factors for stroke recurrence in young patients with first-ever ischemic stroke: A meta-analysis

Xia Y, Liu H, Zhu R
Contents

**SCIENTOMETRICS**

6132  Unveiling the hidden world of gut health: Exploring cutting-edge research through visualizing randomized controlled trials on the gut microbiota


**CASE REPORT**

6147  Rivaroxaban for the treatment of heparin-induced thrombocytopenia with thrombosis in a patient undergoing artificial hip arthroplasty: A case report

  Lv FF, Li MY, Qu W, Jiang ZS

6154  Mepolizumab induced palmoplantar psoriasis: A case report

  Artosi F, Diluvio L, Vultaggio M, Campione E, Bianchi L

6159  Early diagnosis of renal pelvis villous adenoma: A case report

  Li LL, Song PX, Xing DF, Liu K

6165  Identification of the dominant loop of a dual-loop macro-reentry left atrial flutter without prior intervention using high-density mapping technology: A case report

  Yu SD, Chu YP

6170  Surgery for fibrous dysplasia associated with aneurysmal-bone-cyst-like changes in right proximal femur: A case report

  Xie LL, Yuan X, Zhu HX, Pu D

6176  Efficacy of abatacept treatment in a patient with enteropathy carrying a variant of unsignificance in CTLA4 gene: A case report

  Musabak U, Erdoğan T, Ceylaner S, Özbek E, Suna N, Özdemir BH

6183  Postpartum hemophagocytic lymphohistiocytosis: A case report

  An JH, Aho JH

6189  Non-arteritic anterior ischemic optic neuropathy combined with branch retinal vein obstruction: A case report

  Gong HX, Xie SY

6194  Large colonic lipoma with a laterally spreading tumor treated by endoscopic submucosal dissection: A case report

  Bae JY, Kim HK, Kim YJ, Kim SW, Lee Y, Ryu CB, Lee MS

6200  T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report

  Park S, Jeong EJ, Kang JH, Lee GW, Go SI, Lee DH, Koh EH

6206  Severe inflammatory disorder in trisomy 8 without myelodysplastic syndrome and response to methylprednisolone: A case report

  Pan FY, Fan HZ, Zhuang SH, Pan LF, Ye XH, Tong HJ
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6213</td>
<td>Aggressive variant prostate cancer: A case report and literature review</td>
<td>Weng XT, Lin WL, Pan QM, Chen TF, Li SY, Gu CM</td>
</tr>
<tr>
<td>6231</td>
<td>Left epigastric isolated tumor fed by the inferior phrenic artery diagnosed as ectopic hepatocellular carcinoma: A case report</td>
<td>Liu HB, Zhao LH, Zhang YJ, Li ZF, Li L, Huang QP</td>
</tr>
<tr>
<td>6240</td>
<td>Squamous cell carcinoma associated with endometriosis in the uterus and ovaries: A case report</td>
<td>Zhang JM, Zheng CW, Li XW, Fang ZY, Yu MX, Shen HY, Ji X</td>
</tr>
<tr>
<td>6246</td>
<td>Intestinal obstruction due to giant liver cyst: A case report</td>
<td>Liu HB, Zhao LH, Zhang YJ, Li ZF, Li L, Huang QP</td>
</tr>
<tr>
<td>6274</td>
<td>Variant of Guillain-Barré syndrome with anti-sulfatide antibody positivity and spinal cord involvement: A case report</td>
<td>Liu H, Lv HG, Zhang R</td>
</tr>
<tr>
<td>6289</td>
<td>Collision tumor of primary malignant lymphoma and adenocarcinoma in the colon diagnosed by molecular pathology: A case report and literature review</td>
<td>Jiang M, Yuan XP</td>
</tr>
<tr>
<td>6298</td>
<td>Successful resolution of gastric perforation caused by a severe complication of pancreatic walled-off necrosis: A case report</td>
<td>Suh HJ, Cho CH, Kim DH</td>
</tr>
</tbody>
</table>
6311  Delayed diagnosis of abdominal Henoch-Schonlein purpura in children: A case report

Guo H, Wang ZL, Tao Z
ABOUT COVER
Editorial Board Member of *World Journal of Clinical Cases*, Vikram K Mahajan, MD, Professor, Dermatology, Venereology and Leprosy, Dr. Radhakrishnan Government Medical College, Kangra 177001, Himachal Pradesh, India. vkm1@rediffmail.com

AIMS AND SCOPE
The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING
The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstars Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJCC as 1.1; IF without journal self cites: 1.1; 5-year IF: 1.3; Journal Citation Indicator: 0.26; Ranking: 133 among 167 journals in medicine, general and internal; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Hua-Ge Yu; Production Department Director: Xu Guo; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL
*World Journal of Clinical Cases*

ISSN
ISSN 2307-8960 (online)

LAUNCH DATE
April 16, 2013

FREQUENCY
Thrice Monthly

EDITORS-IN-CHIEF
Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2307-8960/editorialboard.htm

PUBLICATION DATE
September 16, 2023

COPYRIGHT
© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Efficacy of tolvaptan in an infant with syndrome of inappropriate antidiuretic hormone secretion associated with holoprosencephaly: A case report

Mari Mori, Satoru Takeshita, Nami Nakamura, Yuki Mizuno, Akiko Tomita, Mineyoshi Aoyama, Hiroki Kakita, Yasumasa Yamada

CASE REPORT

BACKGROUND
Holoprosencephaly (HPE) is a congenital malformation with various degrees of incomplete separation of the cerebral hemispheres due to differentiation disorders of the forebrain. Although HPE with diabetes insipidus due to associated pituitary dysfunction has been reported, HPE with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) is very rare. Tolvaptan, a vasopressin V2 receptor antagonist, is effective in adults with SIADH. However, there is no report of its efficacy in infants with SIADH. The purpose of this report is to demonstrate that tolvaptan is effective for SIADH in infants and that administration of tolvaptan eliminates the need for restriction of water intake and sodium administration.

CASE SUMMARY
A 2414-g female infant was born at 38 wk by normal vaginal delivery. Facial anomalies and head magnetic resonance imaging indicated semilobar HPE. After birth, she had hyponatremia due to SIADH and was treated using water and sodium restriction. However, she developed an exaggerated response to the fluid restrictions, resulting in large fluctuations in serum sodium levels. Subsequent administration of tolvaptan improved the fluctuations in serum sodium levels.
without the need for adjustment of water or sodium administration. Serum sodium was maintained within the normal range after discontinuation of tolvaptan at 80 d of life. There were no side effects, such as hypernatremia or liver dysfunction, during the administration of tolvaptan.

**CONCLUSION**
This is the first report on the safety and efficacy of tolvaptan in an infant with SIADH associated with HPE.

**Key Words:** Tolvaptan; Holoprosencephaly; Antidiuretic hormone; Syndrome of inappropriate secretion of antidiuretic hormone; Hyponatremia; Case report

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Holoprosencephaly with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) is very rare. The main treatments for SIADH are restriction of water intake and sodium administration, which could inhibit the infant’s growth. Tolvaptan, a vasopressin V2 receptor antagonist, is effective in adults with SIADH but has not been reported in infants. In the present neonatal case, the patient developed SIADH, and a restriction of water intake and sodium administration caused the fluctuations in serum sodium levels. Subsequent administration of tolvaptan improved the serum sodium level. Tolvaptan could be a novel standard treatment for infants with SIADH.

**INTRODUCTION**
Holoprosencephaly (HPE) is a congenital malformation in which ventralization of the forebrain, which forms the left and right cerebral hemispheres, is incomplete, due to gene mutations involved in ventral induction of the forebrain, such as SHH, SIX3, and ZIC2[1-5]. HPE causes malformations in the cerebral hemispheres, deep brain structures, olfactory bulbs, and visual bulbs, and facial malformations in the form of interocular narrowing, flat nasal bridge, a single nostril, cleft lip and palate, and a single maxillary central incisor[1,6,7]. Furthermore, HPE might be associated with various degrees of hypothalamic-pituitary dysfunction[1,6-10]. In particular, pituitary dysfunction results in partial or global hyposecretion of anterior lobe hormones and hyposecretion of posterior lobe hormones[1,6-10]. Diabetes insipidus (DI) is generally a common complication of HPE[1,6-10], and HPE with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) is very rare.

The main treatments for infants with SIADH are restriction of water intake and sodium administration[11]. However, these treatments might inhibit the infants’ growth, while also increasing morbidity and mortality in neonates[12,13]. In recent years, tolvaptan, a vasopressin V2 receptor antagonist, has been reported to improve hyponatremia by promoting free water excretion via the renal collecting duct in adults with SIADH[14,15]. However, there are no reports of tolvaptan improving SIADH associated with HPE.

We report herein an infant with SIADH associated with HPE in whom tolvaptan improved hyponatremia, with prevention of the fluctuation in serum sodium levels without limitation of water and sodium administration. This is the first case report showing the efficacy and safety of tolvaptan in an infant with SIADH in association with HPE.

**CASE PRESENTATION**

**Chief complaints**
A 2414-g female infant was born at 38 wk by normal vaginal delivery. Her Apgar score was 8 and 9 at one and five minutes, respectively. She had no respiratory problems or other symptoms but was admitted to the neonatal intensive care unit promptly after birth because HPE was suspected prenatally.

**History of present illness**
The patient had been suspected of having HPE on a fetal echo since the prenatal period.

**Personal and family history**
The patient had no significant family history.
**Physical examination**
The patient had several facial anomalies, including a cleft lip, closely spaced eyes, a depressed nasal bridge, and an absent nasal septum.

**Laboratory examinations**
At birth, no abnormalities were observed in laboratory examinations.

**Imaging examinations**
Head magnetic resonance imaging (MRI) was taken at 3.0 Tesla with 0.8 mm slices to evaluate brain morphology on the 3rd d of life, which revealed a fusion of the frontal region, an interhemispheric fissure in the occipital region, and normal pituitary lobes (Figure 1A and B). The posterior pituitary lobe, which is high-signal on T1-weighted images, is small and shifted upward, suggesting an ectopic posterior pituitary stalk (Figure 1C and D).

**FINAL DIAGNOSIS**
Based on the MRI results, the patient was diagnosed with semilobar HPE.

**TREATMENT**
Figure 2 shows the patient’s clinical course of water intake, serum sodium level, and urine output. On the 2nd d of life, her urine output was 2.4 mL/kg/h and her serum sodium level was 123 mEq/L. Urinary sodium concentration at this time was very high, at 150 mEq/L. However, administration of sodium according to the calculated necessary sodium requirement (11 mEq/kg/d) and restriction of water intake (to 88 mL/kg/d) caused an exaggerated reaction, resulting in hypernatremia (serum sodium level 151 mEq/L) and increased urine output (5.1 mL/kg/h) on the next day. Blood hormone evaluation on the 7th d of life showed that serum adrenocorticotropic hormone (ACTH) and cortisol levels were relatively preserved (ACTH: 21.2 pg/mL; cortisol: 7.0 µg/dL), and thyroid function was normal (free T3: 1.94 pg/mL; free T4: 1.37 ng/dL; thyroid-stimulating hormone: 1.032 µU/mL), suggesting the preservation of anterior pituitary function.

On the 9th d of life, hyponatremia (serum sodium level 119 mEq/L) and decreased urine output (2.8 mL/kg/h) appeared again. Serum osmolality was 246 mOsm/L and urine osmolality was 444 mOsm/L, and serum antidiuretic hormone (ADH) was 1.1 pg/mL. SIADH was diagnosed based on these data [16,17]. Regulation of water intake and sodium administration again caused an exaggerated reaction in terms of serum sodium levels, with no improvement in the fluctuation of serum sodium. Thus, oral tolvaptan was started at a dose of 0.14 mg/kg/d on the 10th d of life. Thereafter, urine output increased and stabilized, and hyponatremia improved without restriction of water or sodium administration.

**OUTCOME AND FOLLOW-UP**
The patient’s serum sodium levels remained within the normal range even after discontinuation of tolvaptan at 80 d of life. There were no side effects of administration of tolvaptan, such as hypernatremia or liver dysfunction.

**DISCUSSION**
Pituitary dysfunction is often present in HPE, and central DI caused by hyposecretion of ADH is one of the most common complications of HPE [1,6-10]. However, this patient had SIADH, and it was difficult to regulate the serum sodium instability with only sodium administration and regulation of water intake. The purpose of this report is to demonstrate that tolvaptan is effective for SIADH in infants and that administration of tolvaptan eliminates the need for restriction of water intake and sodium administration.

Osmoreceptors located in the anteroventral wall of the third ventricle sense changes in plasma osmolality, and transmit signals to ADH neurons in the hypothalamus to regulate ADH secretion [1,6,18]. Four mechanisms of osmotically regulated ADH secretion have been reported in SIADH: Erratic ADH release, reset osmostat, persistent ADH release with low plasma osmolality, and normal osmoregulated ADH secretion [19]. In fact, ADH was secreted in this case despite hyponatremia, in accordance with the diagnostic criteria for SIADH [17,20]. In addition, serum ACTH and cortisol levels were normal, indicating that anterior pituitary function was well preserved. Based on these results, the fluctuations in serum sodium levels might have been due to a disorder in osmoregulation because of posterior pituitary dysfunction.

ADH activates V2 receptors on the basement membrane in renal collecting duct cells, causing aquaporin-2 channels to move to the apical membrane, and allowing the normally impermeable apical membrane to become permeable to water [17,20]. In SIADH, the inappropriately secreted ADH enhances water reabsorption in the renal collecting duct and increases extracellular fluid volume. By promoting free water excretion, tolvaptan reportedly improves hyponatremia in adult SIADH patients [14-16]. In our case, urine output stabilized and serum sodium levels improved after starting...
Mori M et al. Experience with tolvaptan in an infant.

**Figure 1** Head magnetic resonance imaging. A and B: Coronal view of a T1 weighted image. The left and right cerebral hemispheres are incomplete, and the corpus callosum is absent, and there is a semilobar encephalocele; C and D: Parasagittal view of a T1 weighted image. The triangle indicates an ectopic posterior pituitary stalk.

**Figure 2** Clinical course of the patient. Oral administration of sodium and tolvaptan, water intake, serum sodium level, and urine output are shown. In the "Water intake" and "Serum sodium" chart, the gray band represents the general range of a healthy infant.

tolvaptan administration, without the need for adjustment of water or sodium administration, suggesting its potential efficacy even in infants. Since tolvaptan acts on the renal collecting ducts, it might have potential benefit in stabilizing urine output even in the presence of central nervous system diseases [15,16]. Reportedly, 5.9% of adult SIADH patients treated with tolvaptan experience overly rapid correction of hyponatremia [16]. However, no abnormalities in serum sodium were observed in this patient after the administration of tolvaptan. The previous main treatments for infants with SIADH were restriction of water intake and sodium administration. However, these treatments might inhibit the infants' growth, while also increasing morbidity and mortality in neonates [13,14]. In our patient, the administration of tolvaptan resulted in adequate control of serum sodium levels without the need for adjustment of water or sodium administration.
There are some limitations to this study. First, because it is a single case report, there is insufficient evidence of tolvaptan’s efficacy. Second, the outcomes without tolvaptan are unknown because of the lack of controlled trials. However, it is anticipated that the accumulation of other cases will provide stronger evidence.

CONCLUSION

We report an infant with SIADH associated with HPE with an exaggerated response to water restriction and sodium administration. The pathology in this case was presumed to be due to osmoregulatory disorders caused by posterior pituitary dysfunction. Finally, tolvaptan administration enabled stabilization of serum sodium levels. Tolvaptan has the potential to be a novel standard in the treatment of infants with SIADH.

FOOTNOTES

Author contributions: Mori M wrote this manuscript under the supervision of Takeshita S, Aoyama M, Kakita H, and Yamada Y; Nakamura N was involved in the patient’s treatment planning; Mizuno Y and Tomita A confirmed the drug’s side effects and safety; and all authors have read and approved the final manuscript.

Informed consent statement: Informed written consent was obtained from the patient for the publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no competing interests.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Japan

ORCID number: Mari Mori 0000-0001-5016-1230; Satoru Takeshita 0000-0001-7250-8135; Nami Nakamura 0000-0002-5480-8684; Yuki Mizuno 0009-0002-7741-3500; Akiko Tomita 0009-0008-5619-8948; Mineyoshi Aoyama 0000-0002-9976-6465; Hiroki Kakita 0000-0001-5557-0439; Yasumasa Yamada 0009-0004-7214-7164.

S-Editor: Chen YL
L-Editor: Wang TQ
P-Editor: Chen YL

REFERENCES

Mori M et al. Experience with tolvaptan in an infant.


